Skip to Content

Smith & Nephew PLC ADR SNN Stock Quote

| Rating as of

NYSE:SNN

Morningstar‘s Stock Analysis SNN

Valuation
Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

Capital Allocation

INVESTOR

Smith & Nephew Makes Significant Progress With Its CORI Robot; No Change to Our FVE

Debbie S. Wang Senior Equity Analyst

Analyst Note

| Debbie S. Wang |

Narrow-moat Smith & Nephew posted decent third-quarter trading results that largely fell within our expectations, and we’re leaving our fair value estimate unchanged. The company delivered quarterly 5% underlying revenue growth, thanks to strength in advanced wound care, as well as the sports medicine and arthroscopy segment. The orthopedic business offered more muted 2% growth in the quarter. As seen with the firm’s key orthopedic rivals, Smith & Nephew racked up robust growth in knees and hips in the U.S., while revenue growth outside the U.S. remained under pressure.  

Unlock Our Full Analysis With Morningstar Investor

Key Statistics SNN

Company Profile SNN

Business Description

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Contact
Hatters Lane, Building 5, Croxley Park
Watford, Hertfordshire, WD18 8YE, United Kingdom
T +44 1923477100
Industry Medical Devices
Most Recent Earnings Dec 31, 2014
Fiscal Year End Dec 31, 2022
Employees 18,000

Related News SNN